161 related articles for article (PubMed ID: 6110217)
21. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Gomez JC; Crawford AM
J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
[TBL] [Abstract][Full Text] [Related]
22. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
Rémillard S; Pourcher E; Cohen H
J Int Neuropsychol Soc; 2008 Jan; 14(1):110-8. PubMed ID: 18078537
[TBL] [Abstract][Full Text] [Related]
23. [Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients].
Llorca PM; Wolf MA; Lançon C; Bougerol T
Encephale; 1993; 19(5):565-71. PubMed ID: 8306925
[TBL] [Abstract][Full Text] [Related]
24. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
[TBL] [Abstract][Full Text] [Related]
25. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
Convit A; Volavka J; Czobor P; de Asis J; Evangelista C
Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134
[TBL] [Abstract][Full Text] [Related]
26. Commentary on: "Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia." Psychopharmacology (1980) 72:17-19.
Angrist B; Rotrosen J; Gershon S
Psychopharmacology (Berl); 2001 Nov; 158(3):219-21. PubMed ID: 11713609
[No Abstract] [Full Text] [Related]
27. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
[TBL] [Abstract][Full Text] [Related]
28. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
Kramer MS; Last B; Getson A; Reines SA
Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
[TBL] [Abstract][Full Text] [Related]
29. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Tollefson GD; Sanger TM
Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
[TBL] [Abstract][Full Text] [Related]
30. A study of clinical response to different kinds of neuroleptics in first time medicated schizophrenics.
Kadota K
Jpn J Psychiatry Neurol; 1992 Mar; 46(1):127-53. PubMed ID: 1353124
[TBL] [Abstract][Full Text] [Related]
31. B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia.
Ohmori T; Koyama T; Inoue T; Matsubara S; Yamashita I
Biol Psychiatry; 1993 May; 33(10):687-93. PubMed ID: 8102551
[TBL] [Abstract][Full Text] [Related]
32. Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder.
Solomon PR; Crider A; Winkelman JW; Turi A; Kamer RM; Kaplan LJ
Biol Psychiatry; 1981 Jun; 16(6):519-37. PubMed ID: 7196265
[TBL] [Abstract][Full Text] [Related]
33. Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
Lataster J; van Os J; de Haan L; Thewissen V; Bak M; Lataster T; Lardinois M; Delespaul PA; Myin-Germeys I
J Clin Psychiatry; 2011 Oct; 72(10):1397-404. PubMed ID: 21208588
[TBL] [Abstract][Full Text] [Related]
34. Acute amphetamine response predicts antidepressant and antipsychotic responses to lithium carbonate in schizophrenic patients.
van Kammen DP; Docherty JP; Marder SR; Bunney WE
Psychiatry Res; 1981 Jun; 4(3):313-25. PubMed ID: 6115437
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the effects of clozapine, haloperidol, chlorpromazine and d-amphetamine on performance on a time-constrained progressive ratio schedule and on locomotor behaviour in the rat.
Mobini S; Chiang TJ; Ho MY; Bradshaw CM; Szabadi E
Psychopharmacology (Berl); 2000 Sep; 152(1):47-54. PubMed ID: 11041315
[TBL] [Abstract][Full Text] [Related]
36. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.
Goldberg TE; Bigelow LB; Weinberger DR; Daniel DG; Kleinman JE
Am J Psychiatry; 1991 Jan; 148(1):78-84. PubMed ID: 1984711
[TBL] [Abstract][Full Text] [Related]
37. Positive and negative symptoms: is their change related?
Czobor P; Volavka J
Schizophr Bull; 1996; 22(4):577-90. PubMed ID: 8938912
[TBL] [Abstract][Full Text] [Related]
38. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.
Suzuki K; Awata S; Takano T; Ebina Y; Iwasaki H; Matsuoka H
Psychiatry Clin Neurosci; 2005 Aug; 59(4):481-9. PubMed ID: 16048455
[TBL] [Abstract][Full Text] [Related]
39. Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.
van Kammen DP; Docherty JP; Marder SR; Rayner JN; Bunney WE
Arch Gen Psychiatry; 1982 Mar; 39(3):275-81. PubMed ID: 6802100
[TBL] [Abstract][Full Text] [Related]
40. Measurement of depression and negative symptoms in schizophrenia.
Goldman RS; Tandon R; Liberzon I; Greden JF
Psychopathology; 1992; 25(1):49-56. PubMed ID: 1351305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
